Nail disorders: unapproved treatments.

摘要: In surveying the most common nail disorders, onychomycosis and psoriasis, very few Food & Drug Administration (FDA) approved treatments exist. Onychomycosis accounts for approximately 50% of all disease nail. Until recently only griseofulvin ketoconazole were FDA approved. last decade, several new in Europe followed by United States Canada, these include itraconazole terbinafine. More recently, received approval as pulse therapy fingernail onychomycosis. This review will cover non-FDA with dermatophytes, which account 90% infections, nondermatophyte moulds, yeast children there are no therapies. Nail psoriasis is often a stubborn disease, but it may respond partially to wide range therapeutic measures used alone or combination. Unfortunately, benefits various not well documented medical literature. The response PUVA, other forms photo/radiation therapy, systemic terms cutaneous involvement, treatment modalities. Onychomycosis-Dermatophytes